C12N 9/003
Dihydrofolate reductase [dhfr]
Official title: {Dihydrofolate reductase [DHFR] (1.5.1.3)}
C12N9/003 (Dihydrofolate reductase [dhfr]) appears on 128 US grants and 155 published applications in this corpus.
Search patents in C12N- Granted patents
- 128
- Published applications
- 155
- Assignees
- 91
- Inventors
- 325
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 2 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 4 | 0 |
| 1997 | 1 | 0 |
| 1998 | 8 | 0 |
| 1999 | 3 | 0 |
| 2000 | 1 | 0 |
| 2001 | 7 | 1 |
| 2002 | 8 | 3 |
| 2003 | 9 | 2 |
| 2004 | 0 | 4 |
| 2005 | 2 | 0 |
| 2006 | 1 | 4 |
| 2007 | 3 | 5 |
| 2008 | 3 | 3 |
| 2009 | 1 | 0 |
| 2010 | 3 | 6 |
| 2011 | 0 | 2 |
| 2012 | 1 | 3 |
| 2013 | 3 | 2 |
| 2014 | 0 | 4 |
| 2015 | 3 | 4 |
| 2016 | 2 | 7 |
| 2017 | 5 | 5 |
| 2018 | 6 | 10 |
| 2019 | 5 | 11 |
| 2020 | 6 | 13 |
| 2021 | 4 | 13 |
| 2022 | 6 | 13 |
| 2023 | 4 | 10 |
| 2024 | 6 | 11 |
| 2025 | 11 | 9 |
| 2026 | 6 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Small molecules for dual function positron emission tomography (PET) and cell suicide switches4 Aug 2026US 12,697,403 B2The Trustees of the University of Pennsylvania
- Compositions and methods for DHFR tunable protein regulation28 Apr 2026US 12,612,637 B2Obsidian Therapeutics, Inc.
- IL-13 receptor alpha 2 targeted, zetakine directed T cell immunotherapy21 Apr 2026US 12,606,603 B2Seattle Children's Hospital
- Complement component 1s (C1s) deficient cells for production of vaccines and biopharmaceutical proteins24 Feb 2026US 12,559,526 B2The Regents of the University of California
- Destabilising domains for conditionally stabilising a protein27 Jan 2026US 12,534,711 B2Braingene AB
- Analytical device for real time luminescence during temperature hold and ramp as used in real time cellular thermal shift assay1 Oct 2026US 2026/0297593 A1The United States of America, as represented by the Secretary, Department of Health and Human Serv
- Inducible programmed cell death-1 (pd1)-cytokine chimera for potentiated immune cell function24 Sep 2026US 2026/0284108 A1Seattle Children's Hospital d/b/a Seattle Children's Research Institute
- Production cell lines with targeted integration sites17 Sep 2026US 2026/0275373 A1Seagen Inc.
- Peptide expression constructs and uses thereof20 Aug 2026US 2026/0242414 A1Kyoto Prefectural Public University Corporation
- Il-13 receptor alpha 2 targeted, zetakine directed t cell immunotherapy2 Jul 2026US 2026/0184753 A1Seattle Children's Hospital d/b/a Seattle Children's Research Institute
Most cited
By later US patents
- Human tissue plasminogen activator136US 4,766,075 AGenentech, Inc. · 1988
- Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues119US 6,586,207 B2California Institute of Technology · 2003
- Method of generating multiple protein variants and populations of protein variants prepared thereby96US 5,521,077 ALeland Stanford Junior University · 1996
- Methods for diagnosing, preventing, and treating developmental disorders due to a combination of genetic and environmental factors79US 6,210,950 B1University of Medicine and Dentistry of New Jersey · 2001
- Methods of generating desired amino-terminal residues in proteins51US 5,093,242 AMassachusetts Institute of Technology · 1992